Safety, efficacy, and patient selection of ripasudil in patients with uncontrolled glaucoma with maximum conventional medical therapy

PURPOSE: Ripasudil hydrochloride hydrate (0.4%) is the first Rho-associated protein kinase (ROCK) inhibitor eye drop that lowers intraocular pressure (IOP) by increasing conventional aqueous outflow through the trabecular meshwork and Schlemm’s canal. We aimed to evaluate the safety and efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jethva, Jignesh, Bhagat, Purvi, Prajapati, Kamini, Tank, Gunjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Special Focus, Glaucoma, Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359231/
https://www.ncbi.nlm.nih.gov/pubmed/35647972
http://dx.doi.org/10.4103/ijo.IJO_3145_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359231/
https://www.ncbi.nlm.nih.gov/pubmed/35647972
http://dx.doi.org/10.4103/ijo.IJO_3145_21

Ejemplares similares